Nwam LLC Cuts Position in Pfizer Inc. (NYSE:PFE)

Nwam LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 1.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,336 shares of the biopharmaceutical company’s stock after selling 576 shares during the quarter. Nwam LLC’s holdings in Pfizer were worth $1,572,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Pfizer in the first quarter valued at about $315,000. Edgestream Partners L.P. acquired a new stake in Pfizer during the 1st quarter valued at approximately $243,000. Bellevue Group AG grew its stake in Pfizer by 48.0% during the 1st quarter. Bellevue Group AG now owns 33,834 shares of the biopharmaceutical company’s stock valued at $939,000 after purchasing an additional 10,966 shares in the last quarter. Ceeto Capital Group LLC grew its stake in Pfizer by 2.4% during the 1st quarter. Ceeto Capital Group LLC now owns 42,250 shares of the biopharmaceutical company’s stock valued at $1,172,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Perritt Capital Management Inc. grew its stake in Pfizer by 8.6% during the 1st quarter. Perritt Capital Management Inc. now owns 16,283 shares of the biopharmaceutical company’s stock valued at $452,000 after purchasing an additional 1,284 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PFE shares. Sanford C. Bernstein started coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. UBS Group raised their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.92.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.63 on Friday. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm has a market capitalization of $145.24 billion, a PE ratio of 34.64, a P/E/G ratio of 0.80 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business’s fifty day moving average price is $28.21 and its two-hundred day moving average price is $28.57.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same period last year, the firm posted ($0.17) EPS. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.55%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is currently 227.03%.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.